Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar 22;131(12):1275-1291.
doi: 10.1182/blood-2017-09-801498. Epub 2018 Jan 12.

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

Gerrit J Schuurhuis  1 , Michael Heuser  2 , Sylvie Freeman  3 , Marie-Christine Béné  4 , Francesco Buccisano  5 , Jacqueline Cloos  1   6 , David Grimwade  7 , Torsten Haferlach  8 , Robert K Hills  9 , Christopher S Hourigan  10 , Jeffrey L Jorgensen  11 , Wolfgang Kern  8 , Francis Lacombe  12 , Luca Maurillo  5 , Claude Preudhomme  13 , Bert A van der Reijden  14 , Christian Thiede  15 , Adriano Venditti  5 , Paresh Vyas  16 , Brent L Wood  17   18 , Roland B Walter  17   19 , Konstanze Döhner  20 , Gail J Roboz  21 , Gert J Ossenkoppele  1
Affiliations
Review

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

Gerrit J Schuurhuis et al. Blood. .

Abstract

Measurable residual disease (MRD; previously termed minimal residual disease) is an independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is important for risk stratification and treatment planning, in conjunction with other well-established clinical, cytogenetic, and molecular data assessed at diagnosis. MRD can be evaluated using a variety of multiparameter flow cytometry and molecular protocols, but, to date, these approaches have not been qualitatively or quantitatively standardized, making their use in clinical practice challenging. The objective of this work was to identify key clinical and scientific issues in the measurement and application of MRD in AML, to achieve consensus on these issues, and to provide guidelines for the current and future use of MRD in clinical practice. The work was accomplished over 2 years, during 4 meetings by a specially designated MRD Working Party of the European LeukemiaNet. The group included 24 faculty with expertise in AML hematopathology, molecular diagnostics, clinical trials, and clinical medicine, from 19 institutions in Europe and the United States.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: M.-C.B. received research support (Harmonemia project) from Beckman Coulter. J.C. received research funding from Helsinn Healthcare, Janssen Pharmaceuticals, Merus, and Takeda. S.F. received support from National Institute for Health Research, CRUK, and Bloodwise. T.H. and W.K. are both part owners of Munich Leukemie Laboratory. C.S.H. received research funding from Merck and Sellas. G.J.O. provided consultancy services to Janssen and Sunesis; served on the advisory board for Novartis, Pfizer, BMS, Janssen, Sunesis, Celgene, Karyopharm, Amgen, and Seattle Genetics; and received research funding from Novartis, Janssen, Celgene, Immunogen, and Becton Dickinson. G.J.R. provided consultancy services to AbbVie, Amgen, Amphivena Therapeutics, Astex Pharmaceuticals, Array BioPharma Inc., Celgene, Clovis Oncology, CTI BioPharma, Genoptix, Immune Pharmaceuticals, Janssen Pharmaceutica, Jazz Pharmaceuticals, Juno Therapeutics, MedImmune, Novartis, Onconova Therapeutics, Orsenix, Pfizer, Roche/Genentech, and Sunesis Pharmaceuticals and received research support from Cellectis. G.J.S. received research funding from Novartis, Janssen, Immunogen, and Becton Dickinson. C.T. is part Chief Research Officer and Chief Executive Officer and owner of AgenDix GmbH, a company performing molecular diagnostics. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
MRD scenarios and reporting. (A) MFC MRD scenarios. (B) MFC MRD scenario. Example of MFC MRD report template.
See this image and copyright information in PMC

Comment in

  • Consensus on MRD in AML?
    Paietta E. Paietta E. Blood. 2018 Mar 22;131(12):1265-1266. doi: 10.1182/blood-2018-01-828145. Blood. 2018. PMID: 29567752 No abstract available.

References

    1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136-1152. - PubMed
    1. Papaemmanuil E, Gerstung M, Bullinger L, et al. . Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209-2221. - PMC - PubMed
    1. Walter RB, Othus M, Burnett AK, et al. . Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia. 2015;29(2):312-320. - PMC - PubMed
    1. Hourigan CS, Gale RP, Gormley NJ, Ossenkoppele GJ, Walter RB. Measurable residual disease testing in acute myeloid leukaemia. Leukemia. 2017;31:1482-1490. - PubMed
    1. Baer MR, Stewart CC, Dodge RK, et al. . High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood. 2001;97(11):3574-3580. - PubMed

Publication types